Zacks.com on MSN16h
Amgen Shrugs Off Bone Density Concerns Related to Obesity CandidateKey Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
GlobalData on MSN22h
Amgen speaks out about bone density concerns with obesity drugAmgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback